Structure-guided identification and functional evaluation of small-molecule candidates predicted to target the LAG-3/MHC-II interface.
In the MC38 syngeneic tumor model, both Z21 and Z28, when used in combination with anti-PD-1, reduced tumor growth, accompanied by increased frequency of tumor-infiltrating CD8+ T cells, and the in vitro and in vivo results support Z21 and Z28 as prioritized small-molecule candidates for further investigations.